Fig. 5
Cytotoxicity assays for drug treatments performed with CRISPR-ZR75-1 cells (WT) and ZR75-1 cells (variant). a Relative survival of CRISPR-ZR75-1 and ZR75-1 cells determined by MTS after treatment with 4-OH-TAM, raloxifene, olaparib or cisplatin for 3Ā days. b In the presence of 0.01 nM E2, cells were treated with 4-OH-TAM (1Ā Ī¼M) or raloxifene (3.16Ā Ī¼M) together with various concentrations of olaparib. Each data point of the variant cells was normalized as a percentage of their respective data point of the WT cells. Area under the curve was measured and comparisons were performed by unpaired t test. p values are indicated. 4-OH-TAM 4-hydroxytamoxifene, E2 estradiol, Ral raloxifene